The United States has abruptly ceased its HIV funding for South Africa, a nation that relies on international aid to treat 8 million people living with the virus. In response, the United Kingdom has pledged £200 million to fill the immediate gap, but experts warn this is a temporary fix for a systemic crisis.
South Africa accounts for nearly 20% of the global HIV burden. American support, primarily through the President's Emergency Plan for AIDS Relief (PEPFAR), has been a cornerstone of the country’s antiretroviral programme since 2004. The cessation, effective immediately, leaves a void of roughly $400 million annually. The UK’s pledge, while substantial, covers only half of that for a single year.
“This is like turning off a life-support machine and then offering a band-aid,” said Dr. Lindiwe Mthembu, an epidemiologist at the University of Cape Town. “We have the infrastructure and the will. What we lack is predictable funding.”
The timing is particularly grim. New HIV infections in South Africa have declined by 60% since 2010, but progress has plateaued. The country is grappling with a new wave of infections among young women, a group that accounts for 40% of new cases. Treatment interruptions can lead to viral rebound, drug resistance, and increased transmission.
The UK’s Department of Health and Social Care confirmed the £200m package will be channelled through the Global Fund to Fight AIDS, Tuberculosis and Malaria. However, this fund is itself under strain, with donor fatigue evident across Europe.
“The numbers are stark,” said Professor James Walker, a public health analyst at King’s College London. “Without sustained investment, we risk a resurgence that could erase two decades of gains. HIV is not like a flu; it requires lifelong treatment. Interruptions are catastrophic.”
South Africa’s health system, already burdened by tuberculosis and a high rate of non-communicable diseases, cannot absorb this loss without rationing care. Clinics may have to turn away new patients or switch to less effective regimens. The psychological impact on patients is also a concern; many have come to rely on a steady supply of antiretrovirals.
The US decision appears to be tied to shifting foreign policy priorities under the current administration, which has sought to reduce overseas commitments. Critics argue that this is short-sighted. “Every dollar spent on HIV treatment saves lives and economies,” said Dr. Mthembu. “If we let this disease flare again, it will cost more in the long run.”
The UK’s intervention is a stopgap. It buys time for South Africa to seek alternative donors or increase domestic funding, but the country’s economy is still recovering from the pandemic and faces high unemployment. The UK itself is under fiscal pressure, with its overseas aid budget reduced from 0.7% to 0.5% of gross national income in 2021.
“This is a classic tragedy of the commons,” said Professor Walker. “Global health security is a collective good. We cannot have one nation unilaterally withdrawing without consequences that cross borders.”
For now, millions in South Africa wait for clarity. The UK’s pledge ensures that no one will immediately lose access to treatment, but the underlying instability remains. The HIV pandemic is not over, and this funding gap is a stark reminder that progress is fragile.
The world is watching. If the US does not reverse its decision, the burden will fall on other nations and on the people living with HIV themselves. As one patient in Soweto put it: “We are not numbers. We are lives held together by pills.” The science tells us that those pills must keep coming.